Table 3. SARS-CoV-2 seroprevalence among vaccinated participants (n = 1685).
| SARS-CoV-2 Seropositive | SARS-CoV-2 Seronegative | Adjusted Odds Ratio | ||||
|---|---|---|---|---|---|---|
| n | (%) | n | (%) | aOR | (95% CI) | |
| Vaccination status | ||||||
| Partially vaccinated | 123 | (70.3) | 52 | (29.7) | 0.74 | (0.51–1.07) |
| Full primary series | 1106 | (74.9) | 370 | (25.1) | 1 | (ref) |
| Vaccine type | ||||||
| Oxford/AstraZeneca (ChAdOx1-S) | 150 | (64.9) | 81 | (35.1) | 1 | (ref) |
| J&J/Janssen (Ad.26.COV2.S) | 965 | (75.7) | 309 | (24.3) | 1.28 | (0.92–1.79) |
| Pfizer-BioNTech (BNT162b2) | 50 | (75.8) | 16 | (24.2) | 0.71 | (0.36–1.39) |
| Sinopharm | 32 | (72.7) | 12 | (27.3) | 0.79 | (0.37–1.69) |
| Mixed | 21 | (91.3) | 2 | (8.7) | 2.82 | (0.60–13.26) |
| Other | 7 | (100.0) | 0 | (0.0) | -- | -- |
| Months between first dose and enrollment | ||||||
| <1 month | 290 | (69.5) | 127 | (30.5) | 1 | (ref) |
| 1–5 months | 669 | (75.8) | 214 | (24.2) | 1.58 | (1.19–2.10)* |
| ≥6 months | 223 | (81.4) | 51 | (18.6) | 1.48 | (0.99–2.22) |
aOR = adjusted odds ratio (adjusted for district and enrollment month); CI = confidence interval.
*p<0.05